Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 178 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluoxetine (drug) Clear all

Conditions: Diabetes Mellitus
Interventions: Medtable; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 40 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Chicago, Illinois • Peoria, Illinois

Conditions: Pulmonary Arterial Hypertension
Interventions: Fluoxetine; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 16 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Depression, Opioid Use, Chronic Pain, Anxiety
Interventions: Electronic medical recorded clinical decision support [EMR CDS], Stepped opioid collaborative care model [CCM]; Behavioral
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Older Adults, Anxiety, Depression, Cardiac Surgery, Orthopedic Surgery, Major Surgical Resection of a Thoracic Malignancy, Major Surgical Resection of an Abdominal Malignancy
Interventions: Behavioral Activation, Medication Optimization; Behavioral · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Premenstrual Syndrome
Interventions: Fluoxetine, Calcium, Placebo; Drug
Lead sponsor: Donaghue Medical Research Foundation; Other
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Post Traumatic Stress Disorder
Interventions: Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo, Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo, Intervention C Daridorexant, Intervention C Placebo, Intervention D SLS-002, Intervention D Placebo; Drug
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more

Conditions: Adolescent Depression
Interventions: Fluoxetine, Interpersonal Psychotherapy; Drug · Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 12 Years to 18 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Stroke
Interventions: fluoxetine, placebo; Drug
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Autistic Disorder
Interventions: Fluoxetine (prozac); Drug
Lead sponsor: Neuropharm; Industry
Eligibility: 5 Years to 18 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: Phoenix, Arizona • Sacramento, California • Smyrna, Georgia + 10 more

Conditions: Internalizing Psychopathologies (IPs) Depression and Anxiety
Interventions: SSRI, CBT; Drug · Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 271 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions: Not listed
Lead sponsor: Genelex Corporation; Industry
Eligibility: 65 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more

Conditions: Adolescent Depression
Interventions: Lamotrigine (drug), Fluoxetine (drug), sertraline (drug); Drug
Lead sponsor: MaineHealth; Other
Eligibility: 13 Years to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Portland, Maine

Conditions: Advanced Cancer
Interventions: Olanzapine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anorexia Nervosa, Eating Disorders
Interventions: Fluoxetine, Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Adolescent Depression
Interventions: Fluoxetine, Increased Dose of Interpersonal Psychotherapy, Continue to Receive Initial Dose of Interpersonal Psychotherapy; Drug · Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 12 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bipolar Depression
Interventions: Olanzapine Fluoxetine Combination (OFC), Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Major Depressive Disorder
Interventions: Placebo, Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 819 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 39
States / cities: Garden Grove, California • National City, California • Oceanside, California + 34 more

Conditions: Bipolar Disorder
Interventions: Lithium / Fluoxetine, Lithium / Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: Chicago, Illinois • Philadelphia, Pennsylvania

Conditions: Musculoskeletal Injury
Interventions: Fluoxetine, Calcium; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: 1. Major Depressive Disorder
Interventions: Supplemental TMS, Standard Medication Monotherapy; Device · Drug
Lead sponsor: Sheppard Pratt Health System; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Depression
Interventions: duloxetine, fluoxetine, citalopram, paroxetine, sertraline; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 61
States / cities: Carson, California • Irvine, California • San Diego, California + 58 more

Conditions: Healthy
Interventions: Fluoxetine Hydrochloride, PROZAC WEEKLY®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Colorectal Adenocarcinoma
Interventions: Fluoxetine; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Covid19
Interventions: Fluoxetine, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Search by objective public record fields.

Medtable: An Electronic Medical Record (EMR) Strategy to Promote Patient Medication Understanding and Use

Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension

Opioid Treatment and Recovery Through a Safe Pain Management Program

Behavioral Activation and Medication Optimization for Perioperative Mental Health Feasibility Study

Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS)

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

An Adaptive Treatment Strategy for Adolescent Depression-Continuation

Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke

Extended Management and Measurement of Autism

Negative Valence Brain Targets and Predictors of Anxiety and Depression Treatment

YouScript IMPACT Registry

Lamotrigine in Treatment Resistant Depression in Adolescents

Subcutaneous Olanzapine for Hyperactive or Mixed Delirium

Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa

An Adaptive Treatment Strategy for Adolescent Depression

A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

Prevention of Relapse & Recurrence of Bipolar Depression

Fluoxetine Mitigation Mental Health Study for Patients With Musculoskeletal Trauma

Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study

A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression

90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions

Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer

Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)